Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma

Clinical Development, Respiratory Diseases, Allergy and Inflammation, MedImmune, LLC, Gaithersburg, MD, USA. CORRESPONDENCE: N. Molfino, MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878, USA. E-mail: MolfinoN{at}MedImmune.com Received: November 24, 2009 Accepted January 6, 2010 ABSTRACT Ast...

Full description

Saved in:
Bibliographic Details
Published in:European respiratory review 2010-03, Vol.19 (115), p.46-54
Main Authors: Oh, C. K, Geba, G. P, Molfino, N
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - therapeutic use
Asthma
Asthma - drug therapy
Asthma - immunology
Asthma - metabolism
Humans
interleukin-13
Interleukin-13 - immunology
Interleukin-13 - metabolism
interleukin-4
Interleukin-4 - immunology
Interleukin-4 - metabolism
monoclonal antibody
Reviews
signal transducer and activator of transcription factor-6
Signal Transduction - drug effects
Signal Transduction - immunology
STAT6 Transcription Factor - immunology
STAT6 Transcription Factor - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical Development, Respiratory Diseases, Allergy and Inflammation, MedImmune, LLC, Gaithersburg, MD, USA. CORRESPONDENCE: N. Molfino, MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878, USA. E-mail: MolfinoN{at}MedImmune.com Received: November 24, 2009 Accepted January 6, 2010 ABSTRACT Asthma is a complex, persistent, inflammatory disease characterised by airway hyperresponsiveness in association with airway inflammation. Studies suggest that regular use of high-dose inhaled corticosteroids and long-acting bronchodilators or omalizumab (a humanised monoclonal antibody that binds to immunoglobulin E and is often used as next-step therapy) may not be sufficient to provide asthma control in all patients, highlighting an important unmet need. Interleukin-4, interleukin-13, and the signal transducer and activator of transcription factor-6 are key components in the development of airway inflammation, mucus production, and airway hyperresponsiveness in asthma. Biological compounds targeting these molecules may provide a new therapeutic modality for patients with uncontrolled severe asthma. The purpose of this review is to summarise current studies of compounds targeting the interleukin-4/interleukin-13 pathway and to provide a rationale for the development of such compounds for this use. KEYWORDS: Asthma, interleukin-4, interleukin-13, monoclonal antibody, signal transducer and activator of transcription factor-6
ISSN:0905-9180
1600-0617
DOI:10.1183/09059180.00007609